Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

Bristol Myers Squibb is partnering with the original developer of Leqembi in a new Alzheimer’s disease deal. The large drugmaker said Thursday that it's giving BioArctic $100 million upfront to license ...